Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)
Sponsor: Novartis Pharmaceuticals
A PHASE4 clinical study on Relapsing-remitting Multiple Sclerosis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 10 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE4
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE4
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altenholz-Stift, Germany , Aschaffenburg, Germany , Berlin, Germany , Böblingen, Germany , Celle, Germany , Dortmund, Germany , Dresden, Germany , Erbach im Odenwald, Germany , Frankfurt, Germany , Göttingen, Germany and 14 more locations